| scholarly article | Q13442814 |
| P50 | author | Jun Lu | Q55979634 |
| Tomas N Gustafsson | Q58227533 | ||
| Sangit Kumar | Q59618397 | ||
| Martin E Rottenberg | Q61113293 | ||
| P2093 | author name string | Birger Sjöberg | |
| Arne Holmgren | |||
| Suman K Vodnala | |||
| Lars Engman | |||
| Anna-Lena Gustavsson | |||
| Agneta Tjernberg | |||
| Henrik A Johansson | |||
| P2860 | cites work | Two interacting binding sites for quinacrine derivatives in the active site of trypanothione reductase: a template for drug design | Q24616801 |
| High-resolution structures of oxidized and reduced thioredoxin reductase from Helicobacter pylori | Q27646201 | ||
| Comparative structural, kinetic and inhibitor studies of Trypanosoma brucei trypanothione reductase with T. cruzi | Q27657406 | ||
| Dihydroquinazolines as a Novel Class of Trypanosoma brucei Trypanothione Reductase Inhibitors: Discovery, Synthesis, and Characterization of their Binding Mode by Protein Crystallography | Q27671819 | ||
| Trypanosomes lacking trypanothione reductase are avirulent and show increased sensitivity to oxidative stress | Q28144631 | ||
| Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani | Q28271918 | ||
| Redox control in trypanosomatids, parasitic protozoa with trypanothione-based thiol metabolism | Q28275518 | ||
| Molecular actions of Ebselen—an antiinflammatory antioxidant | Q28291545 | ||
| Trypanothione: a novel bis(glutathionyl)spermidine cofactor for glutathione reductase in trypanosomatids | Q28306157 | ||
| A target-based high throughput screen yields Trypanosoma brucei hexokinase small molecule inhibitors with antiparasitic activity | Q28473648 | ||
| Cerebral vessel laminins and IFN-gamma define Trypanosoma brucei brucei penetration of the blood-brain barrier | Q28510213 | ||
| Investigation of trypanothione reductase as a drug target in Trypanosoma brucei | Q30897674 | ||
| Improved tricyclic inhibitors of trypanothione reductase by screening and chemical synthesis | Q33474992 | ||
| Trypanothione is the primary target for arsenical drugs against African trypanosomes | Q33849836 | ||
| Enzymes of the trypanothione metabolism as targets for antitrypanosomal drug development | Q33960778 | ||
| Metabolism and functions of trypanothione in the Kinetoplastida | Q33972467 | ||
| Ebselen: a substrate for human thioredoxin reductase strongly stimulating its hydroperoxide reductase activity and a superfast thioredoxin oxidant | Q34065084 | ||
| Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase | Q34254828 | ||
| Parasites and the brain: neuroinvasion, immunopathogenesis and neuronal dysfunctions. | Q34640320 | ||
| Specific chemotherapy of Chagas disease: controversies and advances | Q35569069 | ||
| Down-regulation of Leishmania donovani trypanothione reductase by heterologous expression of a trans-dominant mutant homologue: effect on parasite intracellular survival | Q36069752 | ||
| Inhibition of glutathione synthesis as a chemotherapeutic strategy for trypanosomiasis | Q36344549 | ||
| Programmed cell death in African trypanosomes. | Q36612384 | ||
| Targeting Trypanothione Metabolism in Trypanosomatid Human Parasites | Q37782110 | ||
| Low-molecular-mass antioxidants in parasites. | Q37952777 | ||
| Active site of trypanothione reductase. A target for rational drug design. | Q39088644 | ||
| RNA interference identifies two hydroperoxide metabolizing enzymes that are essential to the bloodstream form of the african trypanosome. | Q39594334 | ||
| Antiparasitic prodrug nifurtimox: revisiting its activation mechanism | Q39715054 | ||
| Susceptibility of methicillin-resistant Staphylococcus aureus to the selenium-containing compound 2-phenyl-1,2-benzoisoselenazol-3(2H)-one (PZ51). | Q39819760 | ||
| Depletion of the thioredoxin homologue tryparedoxin impairs antioxidative defence in African trypanosomes | Q40220444 | ||
| Flavoprotein structure and mechanism. 5. Trypanothione reductase and lipoamide dehydrogenase as targets for a structure-based drug design. | Q40481216 | ||
| Azaanalogues of ebselen as antimicrobial and antiviral agents: synthesis and properties | Q40491914 | ||
| Bacillus anthracis thioredoxin systems, characterization and role as electron donors for ribonucleotide reductase | Q41462921 | ||
| Potent, selective, and orally available benzoisothiazolone phosphomannose isomerase inhibitors as probes for congenital disorder of glycosylation Ia. | Q41879491 | ||
| Disruption of the trypanothione reductase gene of Leishmania decreases its ability to survive oxidative stress in macrophages. | Q42123859 | ||
| Rationally designed selective inhibitors of trypanothione reductase. Phenothiazines and related tricyclics as lead structures | Q42152987 | ||
| The dithiol glutaredoxins of african trypanosomes have distinct roles and are closely linked to the unique trypanothione metabolism | Q42394562 | ||
| Drug-resistance of Trypanosoma b. rhodesiense isolates from Tanzania | Q43947251 | ||
| A novel antioxidant mechanism of ebselen involving ebselen diselenide, a substrate of mammalian thioredoxin and thioredoxin reductase | Q44102189 | ||
| Substrate specificity, localization, and essential role of the glutathione peroxidase-type tryparedoxin peroxidases in Trypanosoma brucei | Q45234385 | ||
| The effect of TAO expression on PCD-like phenomenon development and drug resistance in Trypanosoma brucei | Q46229139 | ||
| Inhibitors of Trypanosoma cruzi trypanothione reductase revealed by virtual screening and parallel synthesis | Q46610163 | ||
| Inhibition of bacterial thioredoxin reductase: an antibiotic mechanism targeting bacteria lacking glutathione. | Q53128898 | ||
| Cerebral vessel laminins and IFN-γ define Trypanosoma brucei brucei penetration of the blood-brain barrier | Q58852404 | ||
| Human neutrophils lose their surface Fc gamma RIII and acquire Annexin V binding sites during apoptosis in vitro | Q72386143 | ||
| Inhibition of Trypanosoma cruzi trypanothione reductase by acridines: kinetic studies and structure-activity relationships | Q73364992 | ||
| Inhibition of thioredoxin reductase by a novel series of bis-1,2-benzisoselenazol-3(2H)-ones: Organoselenium compounds for cancer therapy | Q84115829 | ||
| P433 | issue | 38 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Trypanosoma brucei | Q33244 |
| P304 | page(s) | 27456-27468 | |
| P577 | publication date | 2013-07-29 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | Ebsulfur is a benzisothiazolone cytocidal inhibitor targeting the trypanothione reductase of Trypanosoma brucei | |
| P478 | volume | 288 |
| Q89662547 | Computational approaches for drug discovery against trypanosomatid-caused diseases |
| Q35987945 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus |
| Q41479143 | Diglycosyl diselenides alter redox homeostasis and glucose consumption of infective African trypanosomes |
| Q34361091 | Ebselen inhibits hepatitis C virus NS3 helicase binding to nucleic acid and prevents viral replication |
| Q33898663 | Essential multimeric enzymes in kinetoplastid parasites: A host of potentially druggable protein-protein interactions |
| Q37390542 | Exploring the mode of action of ebselen in Trypanosoma brucei hexokinase inhibition |
| Q36059265 | Identification of Ebsulfur Analogues with Broad-Spectrum Antifungal Activity |
| Q51730944 | NADPH-dependent and -independent Disulfide Reductase Systems. |
| Q38695331 | Screening the Medicines for Malaria Venture Pathogen Box across Multiple Pathogens Reclassifies Starting Points for Open-Source Drug Discovery. |
| Q40175261 | Synergistic antibacterial effect of silver and ebselen against multidrug-resistant Gram-negative bacterial infections. |
| Q36076081 | The Oral Antimalarial Drug Tafenoquine Shows Activity against Trypanosoma brucei |
| Q33599669 | The establishment of in vitro culture and drug screening systems for a newly isolated strain of Trypanosoma equiperdum |
Search more.